6 results on '"Moradi, Kamyar"'
Search Results
2. Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double‐blind, placebo‐controlled clinical trial.
- Author
-
Ghazizadeh‐Hashemi, Fatemeh, Bagheri, Sayna, Ashraf‐Ganjouei, Amir, Moradi, Kamyar, Shahmansouri, Nazila, Mehrpooya, Maryam, Noorbala, Ahmad‐Ali, and Akhondzadeh, Shahin
- Subjects
CORONARY artery bypass ,HAMILTON Depression Inventory ,PERCUTANEOUS coronary intervention ,SULFORAPHANE ,CLINICAL trials ,DISEASE remission - Abstract
Aim: Depression has been recognized as one of the disorders associated with cardiac interventions such as percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). In the present study, we evaluated the efficacy and safety of sulforaphane in treatment of depression induced by cardiac interventions. Methods: After initial screening, 66 patients with previous history of at least one cardiac intervention and current mild to moderate depression were randomly assigned to two parallel groups receiving either sulforaphane (n = 33) or placebo (n = 33) for six successive weeks. Efficacy was assessed using the Hamilton Rating Scale for Depression (HAM‐D) at baseline and week 2, 4, and 6. Safety of the treatments was checked during the trial period. Results: Sixty participants completed the clinical trial (n = 30 in each group). Baseline demographic and clinical parameters were all similar among groups. Repeated measures analysis indicated that the sulforaphane group exhibited greater improvement in HAM‐D scores throughout the trial (P < 0.001). Response to treatment (≥50% reduction in the HAM‐D score) rate was higher in the sulforaphane group at trial endpoint (30% vs 6.67%, P = 0.042). Remission (HAM‐D score ≤ 7) rate was also higher in the sulforaphane group; however, the difference was not significant (23.33% vs 3.33%, P = 0.052). Finally, no significant difference was observed between the two groups in terms of frequency of side effects. Conclusions: Sulforaphane could safely improve depressive symptoms induced by cardiac interventions. Further clinical trials with larger sample sizes and longer follow‐up periods are warranted to confirm our results. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
- Author
-
Samaei, Areoo, Moradi, Kamyar, Bagheri, Sayna, Ashraf-Ganjouei, Amir, Alikhani, Rosa, Mousavi, Seiedeh Bentolhoda, Rezaei, Farzin, and Akhondzadeh, Shahin
- Subjects
RISPERIDONE ,ARIPIPRAZOLE ,AMISULPRIDE ,RESVERATROL ,HAMILTON Depression Inventory ,PEOPLE with schizophrenia - Abstract
Background Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia. Methods In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms. Results A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P > .05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F = 1.76, df = 1.88, P = . 180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F = 12.25, df = 2.04, P < . 001; F = 5.42, df = 1.56, P = . 011; F = 7.64, df = 1.48, P = . 003). HDRS scores and its changes, ESRS score, and frequency of other complications were not significantly different between resveratrol and placebo groups. Conclusion Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial.
- Author
-
Dehbozorghi, Sara, Bagheri, Sayna, Moradi, Kamyar, Shokraee, Kamyar, Mohammadi, Mohammad‐Reza, and Akhondzadeh, Shahin
- Subjects
ATTENTION-deficit hyperactivity disorder ,CLINICAL trials ,POTASSIUM channels ,ADVERSE health care events - Abstract
Aim: This study evaluated the efficacy and safety of tipepidine as an add‐on to methylphenidate in the drug treatment of attention‐deficit/hyperactivity disorder (ADHD). Methods: This study was an 8‐week, randomized, parallel group, double‐blind, placebo‐controlled trial recruiting 53 ADHD‐diagnosed children. Patients were randomly divided to receive methylphenidate + tipepidine or methylphenidate + placebo for 8 weeks. Participants were assessed using the parent version of ADHD Rating Scale‐IV and the Clinical Global Impression scale at baseline, at week 4, and at the end of the trial. Moreover, the safety and tolerability of the treatment strategies were compared. Results: On general linear model repeated measures analysis a significant effect was seen for time × treatment interaction on the total and hyperactivity–impulsivity subscales of the Parent ADHD Rating Scale‐IV during the trial period (Greenhouse–Geisser corrected: F = 3.45, d.f. = 1.52, P = 0.049, and F = 5.17, d.f. = 1.52, P = 0.014, respectively). The effect for time × treatment interaction, however, was not significant on Clinical Global Impression‐Severity scale (Greenhouse–Geisser corrected: F = 1.79, d.f. = 1.43, P = 0.182). The frequencies of adverse events were similar between the two groups. Conclusion: Eight weeks of treatment with tipepidine, as a supplementary medication, resulted in satisfactory efficacy and safety of the adjuvant therapy in management of patients with ADHD. Rigorous investigations, however, involving larger sample sizes, more extended treatment periods, and dose responses should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
- Author
-
Karbalaee, Monire, Jameie, Melika, Amanollahi, Mobina, TaghaviZanjani, Fateme, Parsaei, Mohammadamin, Basti, Fatemeh A., Mokhtari, Saba, Moradi, Kamyar, Ardakani, Mohammad-Reza Khodaei, and Akhondzadeh, Shahin
- Subjects
- *
PEOPLE with schizophrenia , *FINGOLIMOD , *CLINICAL trials , *YOGIC therapy - Abstract
Studies have suggested that fingolimod, a sphingosine-1-phosphate receptor modulator, exerts neuroprotective and anti-inflammatory effects. Although fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis, limited studies have investigated its effects in patients with schizophrenia. This study investigated the efficacy and safety of fingolimod adjuvant to risperidone in schizophrenia treatment. This eight-week, randomized, double-blinded, placebo-controlled trial included 80 (clinical trials registry code: IRCT20090117001556N137) patients with chronic schizophrenia. Participants were assigned to two equal arms and received risperidone plus either fingolimod (0.5 mg/day) or a matched placebo. The positive and negative symptom scale (PANSS) was used to measure and compare the effectiveness of treatment strategies at baseline and weeks 2, 4, 6, and 8. Treatment side effects were also compared. Seventy participants completed the trial (35 in each arm). The baseline characteristics of the groups were comparable (P -value > 0.05). There were significant time-treatment interaction effects on negative symptoms (P -value = 0.003), general symptoms (P-value = 0.037), and the PANSS total score (P-value = 0.035), suggesting greater improvement in symptoms following the fingolimod adjuvant therapy. In contrast, the longitudinal changes in positive and depressive symptoms were similar between the groups (P -values > 0.05). Regarding the safety of treatments, there were no differences in extrapyramidal symptoms [assessed by the extrapyramidal symptom rating scale (ESRS)] or frequency of other complications between the fingolimod and the placebo groups (P -values > 0.05). This study indicated that fingolimod is a safe and effective adjuvant agent for schizophrenia treatment. However, further clinical trials are required to suggest extensive clinical application. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
- Author
-
Salehi, Anahita, Namaei, Parsa, TaghaviZanjani, Fateme, Bagheri, Sayna, Moradi, Kamyar, Khodaei Ardakani, Mohammad-Reza, and Akhondzadeh, Shahin
- Subjects
- *
HAMILTON Depression Inventory , *PEOPLE with schizophrenia , *RISPERIDONE , *YOGIC therapy - Abstract
• Patients with schizophrenia can manifest negative symptoms such as functional, verbal, and social performance loss. • Negative symptoms are usually resistant to monotherapy with currently available antipsychotics and require adjunctive treatments. • Anandamide, which is a major component of the endocannabinoid system, is associated with severity of schizophrenia symptoms. • N-palmitoylethanolamide (PEA) is an endogenous analogue of anandamide and has been conventionally used as a medication for its anti-inflammatory and analgesic properties. • In this 8-week, randomized, double-blind, placebo-controlled clinical trial, we investigated the efficacy and safety of adjuvant PEA with risperidone in treatment of chronic schizophrenia and found significant improvement in negative symptoms. Primary negative symptoms of schizophrenia are usually resistant to monotherapy with antipsychotics. The present study sought to assess the efficacy and tolerability of Palmitoylethanolamide (PEA) adjunctive therapy in treatment of negative symptoms in patients with stable schizophrenia. This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone. Outcome measures were the positive and the negative syndrome scale (PANSS), the extrapyramidal symptom rating scale (ESRS), and the Hamilton depression rating scale (HDRS). The primary outcome was change in the negative subscale score during the trial period between the groups. Safety of interventions were controlled and addressed during the trial. A total of 50 participants completed the trial (25 in each group). Baseline characteristics of the groups were comparable (p >0.05). There was significant effect from time-treatment interaction on negative symptoms (p = 0.012) suggesting greater symptom improvement in the PEA group. In contrast, the longitudinal changes in positive symptoms and depressive symptoms were similar between groups (p values>0.05). Safety assessments showed no significant difference regarding extrapyramidal symptoms, measured by ESRS, and also frequency of other complications between PEA and placebo groups (p values>0.05). Adjunctive therapy with PEA and risperidone alleviates schizophrenia-related primary negative symptoms in a safe manner. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.